Over a decade of experience with a yeast recombinant hepatitis B vaccine

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 57-67

  Assad, Safary ^a   Francis, André ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; HEPATITIS B; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MENTAL DEFICIENCY; NEWBORN; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RENAL DIALYSIS; SUBSTANCE ABUSE, INTRAVENOUS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0033588461     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00179-6     Document Type: Article

References (92)

1. Chen H.L., Chang M.H., Ni Y.H., et al. Seroepidemiology of hepatitis B virus infection in children. Ten years of mass vaccination in Taiwan. JAMA. 276:1996;906-908.
2. Gully P.A. Selective risk group strategies in North America. Vaccine. 13:1995;S41-S43.
3. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology. 1:1981;377-385.
4. Crossley K.B., Gerding D.N., Petzel P.A. Acceptance of hepatitis B vaccine by hospital personnel. Inf Cont. 6:1985;147-149.
5. Kane M.A. Global status of hepatitis B immunisation. Lancet. 348:1996;696.
6. Niu M.T. Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly. 4:1996;13-15. [November].
7. World Health Organisation. Weekly Epidemiological Record 1997;72:149-156.
8. Lunn J.A. Hepatitis B vaccination. BMJ. 307:1993;732.
9. Halsey N.A., Duclos P., Van Damme P., Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Pediart Inf Dis J. 18:1999;23-24.
10. Morgan D.R. A code of practice for implementation of the UK hepatitis B immunisation guidelines for the protection of patients and staff. 1995;BMA, London. [edited for British Medical Assoc. Board of Science and Education].
11. Thompson S., Ruff T.A. Hepatitis B vaccination, what are the current international recommendations? Clin Immunother. 3:1995;15-26.
12. André F.E. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. Am J Med. 87:1989;14S-20S.
13. André F.E. Overview of a 5 year clinical experience with a yeast derived hepatitis B vaccine. Vaccine. 8:1990;S74-S78.
14. André F.E., Goilav C., Piot P. Development and clinical studies with a recombinant DNA hepatitis B vaccine. Meheus A., Spiers R. Vaccines for sexually transmitted diseases. 1989;128-133.
15. Crovari P., Cuneo-Crovari P., Icardi G.C., et al. Immunization of young adults with two yeast derived hepatitis B vaccines. Zuckerman A.J., et al. Viral Hepatitis and Liver Disease. 1988;1071-1073 Alan R Liss Inc, New York.
16. Dahl-Hansen E., Siebke J.C., Froland S.S., et al. Immunogenicity of yeast derived hepatitis B vaccine from two different producers. Epidemiol Infect. 104:1990;143-149.
17. Renzulli G., Gottardell L., Canazza S., et al. Immunogenicity of two hepatitis B vaccines produced by means of recombinant DNA technique. 35th Congresso Nazionale de Igiene. Montecatini Termi, Italy. October 21-24. 1992;116-119.
18. Chiaramonte M., Majori S., Ngatchu T., et al. Two different dosages of yeast derived recombinant hepatitis B vaccines, a comparison of immunogenicity. Vaccine. 14:1996;135-137.
19. Schmid K., StrebI H., Heck K.J., Weltle D., Raithel H.J. Efficacy and tolerance of hepatitis B vaccines produced by gene technology a comparative review. Gesundheitswesen. 54:1992;219-222.
20. Hammond G.W., Parker J., Minims L., Tate R., Sekla L., Minuk G. Comparison of immunogenicity of two yeast derived recombinant hepatitis B vaccines. Vaccine. 9:1991;97-100.
21. Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull VMO. 73:1995;529-530.
22. Bock H.L., Kruppenbacher J.P., Sänger R., Hobel W., Clemens R., Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med. 156:1996;2226-2231.
23. Wood R.C., MacDonald K., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 270:1993;2935-2939.
24. Moyes C., Milne A. Immunogenicity of a recombinant yeast derived hepatitis B vaccine (Engerix-B) in children. NZ Med J. 101:1988;162-164.
25. Poovorawan Y., Sanpavat S., Pongpunglert W., Chumdermpadetsuk S., Sentralcul P., Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigenpositive mothers. JAMA. 261:1989;3278-3287.
26. Catania G., Di Ciommo V., Concato C. Vaccination against hepatitis B virus in children and adolescents in a pediatric hospital. Recenti Progressi Med. 87:1996;271-274.
27. Goldfarb J., Medendorp S.V., Garcia H., Nagamori K., Rathfon H., Krause D. Comparison study of the inimunogenicity and safety of 5 and 10 μg dosages of a recombinant hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 15:1996;764-767.
28. Goldfarb J., Medendorp S.V., Nagamori K., Buscarino C., Krause D. Comparison study of the immunogenicity and safety of 5 and 10 μg dosages of a recombinant hepatitis B vaccine in healthy children. Pediatr Infect Dis. 15:1996;768-771.
29. Greenberg D.P., Vadheim C.M., Wong V.K., et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J. 15:1996;590-596.
30. Poovorawan Y., Sanpavat S., Chumdermpadetsuk S., Safary A. Long term hepatitis B vaccine in infants born to hepatitis B E antigen positive mothers. Arch Dis Child Neonatal Fetal. 77:1997;F47-F51.
31. Grob P.J. Unresolved issues in hepatitis B immunization. Hollinger F.B. Viral hepatitis and liver disease. 1990;856-860 Williams & Wilkins, Baltimore.
32. Leroux-Roels G. Nonresponsiveness to hepatitis B vaccine. Hepatocite Int Hepatitis Update. 10:1993;17.
33. Desombere I., Willems A., Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens. 51:1998;593-604.
34. Bock HL, Clemens R, Sänger R, et al. Low and nonresponders do respond after additional hepatitis B vaccine doses. Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy 1996.
35. Kane M. Clinical evaluation of HB vaccine as a component of combination vaccines. Biologicals. 22:1994;403-405.
36. Jilg W., Schmidt M., Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol. 6:1998;201-207.
37. Gesemann M., Scheiermann N. Quantification of hepatitis B vaccine induced antibodies as a predictor of antiHBs persistence. Vaccine. 13:1995;443-447.
38. Ambrosch F., Frisch-Niggemeyer W., Kremsner P., et al. Persistence of vaccine induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J. 63:1987;129-135.
39. West D.J., Calandra G.B. Vaccine induced immunological memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 14:1996;1019-1027.
40. Wismans P.J., van Hattum J., Mudde G.C., Endeman H.J., Poel J., de Gast G.C. Is booster injection with hepatitis B vaccine necessary in healthy responders? J Hepatology. 8:1989;236-240.
41. Lunn J.S. Hepatitis B vaccination. BMJ. 307:1993;732.
42. Lemon S.M., Thomas D.L. Vaccines to prevent viral hepatitis. New Engl J Med. 336:1997;196-204.
43. Aspinall S., Kocks D.J. Antibody decline after hepatitis B vaccination and the effects of boosters. SA Med J. 85:1995;284-293.
44. Tilzey A.J. Hepatitis B vaccine boosting: the debate continues. Lancet. 345:1995;1000-1001.
45. McIntyre P.G. Hepatitis B vaccination follow up. Lancet. 345:1995;1575.
46. Kane M.A. Clinical evaluation of HB vaccine as a component of combination vaccines. Biologicals. 22:1994;403-405.
47. Rosman A.S., Prithwijit B., Galvin K., Lieber C.S. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med. 103:1997;217-222.
48. Dodd R.Y. Transfusion transmitted hepatitis virus infection. Transf Med. 9:1995;137-154.
49. Liang T.J., Bodenheimer H.C. Jr, Yankee R., et al. Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. J Med Virol. 42:1994;151-157.
50. Elghouzzi M.H., Couroucé A.M., Magnius L.O., Lunel F., Lapierre V. Transmission of hepatitis B virus by HBV negative blood transfusion. Lancet. 346:1995;964.
51. Baginski I., Chemin I., Hantz O., et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of post-transfusion hepatitis. Transfusion. 32:1992;215-220.
52. Mannucci P.M., Gringeri A., De Biasi R., et al. Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs. Am J Hematol. 29:1988;211-214.
53. Ribeiro CM, Martins VCL, Santiago MLV, Rocha VG, Viana MB, Proietti FA. Hepatitis B vaccination in hemophiliacs: comparison of two protocols. Rev Invest Clin. 1994. p. 334. [(Spain), supplement].
54. Santagostino E., Mannucci P.M., Gringeri A., et al. Accelerated schedule of hepatitis B vaccination in patients with hemophilia. J Med Virol. 41:1993;95-98.
55. Mazumder M., Sengupta B., De M., Lahiri P., Bhattacharya D.K. Immunosurveillance of transfusion dependent thalassaemia and hepatitis B vaccination. J Assoc Phys India. 41:1993;342-344.
56. Giammanco G., De Grandi V., Pignato S., et al. Yeast derived hepatitis B vaccine in thalassaemic patients: a preliminary report. Postgrad Med J. 63:1987;151-154.
57. De Virgiliis S, Pisu C, Congia M. Transfusional hepatitis B control in thalassemia major. In: Coursaget P, Tong MJ (editors). Progress in hepatitis B immunization. vol. 194. John Libbey Eurotext Ltd. 1990. p. 157-163.
58. Rumi M., Colombo M., Romeo R. Suboptimal response to hepatitis B vaccine in drug users. Arch Intern Med. 151:1991;574-578.
59. Salassa B., Macor A., Zucco M., Nigra E., Spezia C., Soranzo M.L. Anti hepatitis B immunization in drug addicts: establishing a schedule. G Mal Infect Parassit. 46:1994;27-39.
60. Rodrigo J.M., Serra M.A., Aparisi L., et al. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine. 10:1992;798-801.
61. Keet I.P.M., van Doomum G., Safary A., Coutinho R.A. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS. 6:1992;509-510.
62. Tayal S.C., Sankar K.N. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV infected individuals. AIDS. 8:1994;558-559.
63. Hess G, Cheatham-Speth D, Rossol S, Voth R, Clemens R, Hermann K. The effect of vaccination against hepatitis B on the number of DC 4 positive cells in antiHIV positive homosexual men. International conference on molecular aspects of immune response and infectious diseases. Rome, Italy, 1989.
64. Zuin G., Principi N., Tornaghi R., et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine. 10:1992;857-860.
65. Arrazola M.P., de Juanes J.R., Ramos J.T., Aragén A.J., de Codes A.G. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol. 45:1995;339-341.
66. Zuccotti G.V., Riva E., Flumine P., et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Pediatr. 125:1994;70-72.
67. Choudhury S.A., Hodes D.S., Peters V.B. Responses to hepatitis B vaccine boosters in human immunodeficiency virus infected children. Pediatr Infect Dis J. 14:1995;65-67.
68. Grzesiowski P., Sieniawaska M. Efficacy of recombinant hepatitis B vaccine in children with chronic renal failure. Pediatr Nephrol. 8:1994;D43.
69. Fanelli V., Sanna G., Solinas A. Expectation of impaired response to recombinant hepatitis B vaccination. Nephron. 61:1992;293-295.
70. Baralkiewicz G., Juszczyk J. The results of the vaccination against hepatitis B (Engerix-B) among haemodialysis patients. J Hepatol. 21:1994;S162.
71. Fabrizi F., Di Filippo S., Marcelli D., et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Nephron. 72:1996;536-543.
72. Jungers P. Vaccination contre I'hepatite B dans les centres d'hemodialyse. Nephrolgie. 19:1998;37-38.
73. Rault R., Freed B., Nespor S., Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO J. 41:1995;M717-M719.
74. Chang P.C., Schrander-van der Meer A.M., van Dorp W.T., van Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary nonresponding haemodialysis patients. Nephrol Dial Transplant. 11:1996;191-193.
75. Vlassopoulos D., Arvanitis D., Lilis D., Katopodis K., Louizou K., Hadjiconstantinou V. Low repeated doses of intradermal hepatitis B vaccine produce protective levels o antibodies in hemodialysis patients, nonresponding to usual and double multiple doses. J Nephrol. 7:1994;340-341.
76. Marangi A.L., Giordano R., Montanaro A., et al. A successful two-step integrated protocol of antiHBV vaccination in chronic uremia. Nephron. 61:1992;331-332.
77. Marangi A.L., Giordano R., Montanaro A., et al. Hepatitis B virus infection in chronic uremia: longterm follow up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 23:1994;534-542.
78. Yeoh E.K. Hepatitis B virus infection in children. Vaccine. 8:1990;S29-S30.
79. Poovorawan Y., Sanpavat S., Chumdermpadetsuk S., Safary A. Longterm protective efficacy of recombinant hepatitis B vaccine in neonates at risk with or without month 60 booster. Rizzett M., Purcell R.H., Gerin J.I., Verme G. Viral hepatitis and liver disease. 1997;957-959.
80. Lee P.I., Lee C.Y., Huang L.M., Chang M.H. Longterm efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 126:1995;716-721.
81. André F.E., Zuckerman A.J. Review: protective efficacy of hepatitis B vaccines. J Med Virol. 44:1994;144-151.
82. Chaudhary R.K., Perry E., Cleary T.E. Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol. 105:1977;123.
83. McMillan B.C., Hanson R.P., Golumjatnikov R., et al. Hepatitis B surface antigen and antibody: prevalence and persistence in institutionalized and noninstitutionalized persons. Pub Health Rep. 94:1979;262.
84. Perillo R.P., Storch G.A., Bodicky C.J., et al. Survey of hepatitis B viral markers at a public school and a residential institution sharing mentally handicapped students. J Infect Dis. 149:1984;796.
85. Van Damme P., Vrancks R., Safary A., André F., Meheus A. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med. 97:1989;26S-29S.
86. Vellinga A., Van Damme P., Weyler J.J., Vranckx R., Meheus A. Long term effectiveness of hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 17:1999;602-606.
87. Carman W.F., Zanetti A.R., Karayiannis P., et al. Vaccine induced escape mutant of hepatitis B virus. Lancet. 336:1990;325-329.
88. Waters J.A., Kennedy M., Voet P., et al. Loss of the common A determinant of hepatitis B surface antigen by a vaccine induced escape mutant. J Clin Invest. 90:1992;2543-2547.
89. Kane M.A. Clinical evaluation of HB vaccine as a component of combination vaccines. Biologicals. 22:1994;403-405.
90. Andre F.E. Development and clinical application of new polyvalent combined paediatric vaccines. Vaccine. 17:1999;1620-1627.
91. Jilg W. Introduction to current control of hepatitis B as a community health risk. Vaccine. 13:1995;S40.
92. Treadwell T.L., Keeffe E.B., Lake J., et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med. 95:1993;584-588.